---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-120348"
form_type: "8-K"
ticker: null
cik: "0001600132"
company_name: "Bellerophon Therapeutics, Inc."
filed_at: "2023-11-21T23:59:59+00:00"
generated_at: "2026-06-07T22:41:04.247214+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Bellerophon appoints Craig Jalbert President/principal officer amid wind-down; CEO leaves Nov 15

## Summary
- CEO Peter Fernandes and VP Parag Shah separated effective Nov 15, 2023, per previously disclosed separation agreements.
- Craig Jalbert appointed President, Treasurer, Corporate Secretary, principal executive/financial/accounting officer, and director.
- Jalbert, a distressed-business specialist at Verdolino & Lowey, will be compensated $10k/month pre-dissolution, then $50k/year for three years post-dissolution.
- Compensation structure is contingent on stockholder approval of dissolution and board decision to implement.

## SEC filing metadata
- accession: 0001104659-23-120348
- form_type: 8-K
- cik: 0001600132
- company_name: Bellerophon Therapeutics, Inc.
- filed_at: 2023-11-21T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600132/000110465923120348/0001104659-23-120348-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600132/000110465923120348/tm2331228d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-120348
- JSON: https://secwatch.observer/filing/0001104659-23-120348.json
- Plain text: https://secwatch.observer/filing/0001104659-23-120348.txt

## Key facts
- Executive change
  Craig Jalbert was appointed as Director at Bellerophon Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: On November 15, 2023, the Board appointed Craig Jalbert, age 62, as the Company's President, Treasurer and Corporate Secretary and as the Company’s principal executive officer, principal financial officer and principal accounting officer, effective November 15, 2023, and as a member of the Board, effective November 15, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1600132/000110465923120348/0001104659-23-120348-index.htm
- Executive change
  Craig Jalbert was appointed as President at Bellerophon Therapeutics, Inc..
  - Action: appointed
  - Role: President
  source text: On November 15, 2023, the Board appointed Craig Jalbert, age 62, as the Company's President, Treasurer and Corporate Secretary and as the Company’s principal executive officer, principal financial officer and principal accounting officer, effective November 15, 2023, and as a member of the Board, effective November 15, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1600132/000110465923120348/0001104659-23-120348-index.htm
- Executive change
  Peter Fernandes departed as Chief Executive Officer at Bellerophon Therapeutics, Inc..
  - Action: separated
  - Role: Chief Executive Officer
  source text: the board of directors of the Company (the “Board”) set November 15, 2023 as the separation date for the employment of each of Dr. Fernandes and Mr. Shah.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1600132/000110465923120348/0001104659-23-120348-index.htm
- Executive change
  Parag Shah departed as Vice President of Business Operations at Bellerophon Therapeutics, Inc..
  - Action: separated
  - Role: Vice President of Business Operations
  source text: the board of directors of the Company (the “Board”) set November 15, 2023 as the separation date for the employment of each of Dr. Fernandes and Mr. Shah.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1600132/000110465923120348/0001104659-23-120348-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.